2018 turned out to be superb for the pharma and biotech sector with the FDA approval of 59 drugs compared to only 46 drugs approved
Following a downgrade from “hold” to “sell” by Cantor Fitzgerald, the shares of biotechnology company Seattle Genetics (NASDAQ: SGEN) dropped sharply by over 13% at
2018 turned out to be superb for the pharma and biotech sector with the FDA approval of 59 drugs compared to only 46 drugs approved
Following a downgrade from “hold” to “sell” by Cantor Fitzgerald, the shares of biotechnology company Seattle Genetics (NASDAQ: SGEN) dropped sharply by over 13% at
